Literature DB >> 18596584

T regulatory cells in contact hypersensitivity.

Andrea Cavani1.   

Abstract

PURPOSE OF REVIEW: The review summarizes the recent investigations focused on T regulatory cells in hapten diseases. RECENT
FINDINGS: Multiple mechanisms ensure tolerance to small chemicals penetrating the skin. Among these, specific T regulatory cells play a major role in controlling harmful immune responses to environmental antigens. Most of the T regulatory cells involved in this process belongs to the CD4 subset and suppress hapten-specific immune response through the release of IL-10 and through direct interaction with effector T cells, blocking their function.
SUMMARY: Methods for in-vitro and in-vivo expansion of specific T regulatory cells may represent an innovative approach for the cure of contact hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596584     DOI: 10.1097/ACI.0b013e3283079ea4

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  4 in total

Review 1.  [Immunology of contact allergy].

Authors:  S F Martin
Journal:  Hautarzt       Date:  2011-10       Impact factor: 0.751

2.  Superior Suppressive Capacity of Skin Tregs Compared with Lung Tregs in a Model of Epicutaneous Priming.

Authors:  Subhashree Mahapatra; Melanie Albrecht; Abdul M Baru; Tim Sparwasser; Christina Herrick; Anna M Dittrich
Journal:  J Invest Dermatol       Date:  2015-05-22       Impact factor: 8.551

3.  Equine CD4(+) CD25(high) T cells exhibit regulatory activity by close contact and cytokine-dependent mechanisms in vitro.

Authors:  Eman Hamza; Vinzenz Gerber; Falko Steinbach; Eliane Marti
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

4.  The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct Vβ Receptors.

Authors:  Andrew Gibson; Lee Faulkner; Maike Lichtenfels; Monday Ogese; Zaid Al-Attar; Ana Alfirevic; Philipp R Esser; Stefan F Martin; Munir Pirmohamed; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2017-07-07       Impact factor: 5.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.